GlassScriptPhysician profile
Thomas B Reilly
NPI 1750574299
$6,322.22
in general payments reported to CMS, 2019-2025
34 companies · $699 in 2025
The $699 reported for 2025 was more than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
See the full distribution for Pain Medicine (Physical Medicine & Rehabilitation)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,390 · 2020: $1,698 · 2021: $648 · 2022: $519 · 2023: $824 · 2024: $544 · 2025: $699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,504 · Travel and Lodging: $564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,503.95 |
| Travel and Lodging | $563.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,854.80 | 2019-2024 | Proclaim |
| Nevro Corp. | $829.02 | 2019-2024 | Senza |
| Si-Bone, INC. | $641.60 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $388.50 | 2020-2023 | Relistor |
| Scilex Pharmaceuticals INC. | $334.86 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $285.39 | 2019-2021 | |
| Medtronic, INC. | $230.51 | 2021-2024 | Intellis Adaptivestim, Synchromedii |
| Medtronic USA, INC. | $230.00 | 2019-2020 | |
| Nalu Medical, INC. | $201.99 | 2021-2022 | |
| Boston Scientific Corporation | $195.68 | 2023-2025 | G4 Rf Generator, Wavewriter Alpha Prime 16 |
| Collegium Pharmaceutical, INC. | $135.58 | 2020-2025 | Xtampza |
| Abbvie INC. | $128.17 | 2021-2023 | |
| Saluda Medical Americas, INC. | $116.95 | 2024 | Evoke |
| Biodelivery Sciences International, INC. | $113.69 | 2020 | |
| Redhill Biopharma INC. | $95.20 | 2020-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $78.15 | 2019-2021 | |
| Spr Therapeutics, INC | $64.77 | 2022 | |
| Fidia Pharma USA INC. | $45.55 | 2025 | Hymovis, Triluron |
| Allergan, INC. | $31.72 | 2021-2022 | |
| Stimwave Technologies Incorporated | $30.62 | 2019 | |
| Globus Medical, INC. | $29.04 | 2025 | Senza |
| Mdd US Operations, LLC | $26.79 | 2019 | |
| Almatica Pharma LLC | $23.72 | 2021 | |
| Valinor Pharma, LLC | $23.03 | 2023 | Movantik |
| Daiichi Sankyo INC. | $22.37 | 2019 | |
| Leo Pharma INC. | $21.76 | 2023 | Adbry |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Pacira Therapeutics, INC. | $20.90 | 2019 | |
| Curonix LLC | $19.98 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Stryker Corporation | $19.56 | 2024 | Mild Device Kit |
| Amgen INC. | $19.05 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.45 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.10 | 2019 | |
| Electronic Waveform Lab, INC. | $13.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Reilly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.